A Multi Centre Open Label Single Therapy Dose Ranging Study to Characterise the Pharmacokinetics and Tolerability of BTDS 5-20 ug/h in Children Who Require Opioid Analgesia for Moderate to Severe Mouth Pain Secondary to Chemotherapy Induced Mucositis.

Trial Profile

A Multi Centre Open Label Single Therapy Dose Ranging Study to Characterise the Pharmacokinetics and Tolerability of BTDS 5-20 ug/h in Children Who Require Opioid Analgesia for Moderate to Severe Mouth Pain Secondary to Chemotherapy Induced Mucositis.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Pain
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 23 Oct 2012 Planned End Date changed from 1 Apr 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 07 Jul 2012 Additional trial location (Denmark) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top